L3VLUP
ProSign in

SANA · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SANAGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SANA
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterSANAGILD
Q3 2020none listed holders, n.a.25 holders, $14.2bn
Q4 2020none listed holders, n.a.27 holders, $13.4bn
Q1 20214 holders, $398m24 holders, $14.5bn
Q2 20213 holders, $259m18 holders, $14.9bn
Q3 20214 holders, $297m20 holders, $16.4bn
Q4 20214 holders, $206m20 holders, $16.8bn
Q1 20223 holders, $106m28 holders, $13.2bn
Q2 20223 holders, $80m26 holders, $13.6bn
Q3 20223 holders, $74m24 holders, $13.3bn
Q4 20223 holders, $46m32 holders, $21.1bn
Q1 20233 holders, $38m27 holders, $21.8bn
Q2 20233 holders, $76m24 holders, $20.7bn
Q3 20233 holders, $47m24 holders, $20.0bn
Q4 20233 holders, $50m22 holders, $21.5bn
Q1 20244 holders, $171m30 holders, $20.3bn
Q2 20243 holders, $91m28 holders, $18.5bn
Q3 20243 holders, $68m29 holders, $24.2bn
Q4 20242 holders, $26m28 holders, $25.9bn
Q1 20252 holders, $26m33 holders, $32.0bn
Q2 20251 holders, $27m27 holders, $30.9bn
Q3 20251 holders, $41m23 holders, $29.4bn
Q4 20251 holders, $27m25 holders, $34.3bn
Q1 20261 holders, $19m25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
SANA

Sana Biotechnology Inc

Holders
4
Reported value
$171m
Buyers
4
Sellers
0

Breadth +4 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
30
Reported value
$20.3bn
Buyers
17
Sellers
12

Breadth +5 among 93 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SANA (2)

Baillie Gifford & Co, PDT Partners LLC

Only GILD (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →